Gilead Sciences, Inc. (ETR:GIS)
Germany · Delayed Price · Currency is EUR | Market Cap | 117.55B |
| Revenue (ttm) | 24.58B |
| Net Income (ttm) | 5.37B |
| Shares Out | n/a |
| EPS (ttm) | 4.27 |
| PE Ratio | 21.87 |
| Forward PE | 13.21 |
| Dividend | 2.82 (2.98%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 381 |
| Average Volume | 295 |
| Open | 95.20 |
| Previous Close | 94.57 |
| Day's Range | 95.20 - 96.12 |
| 52-Week Range | 73.51 - 111.84 |
| Beta | 0.38 |
| RSI | 45.40 |
| Earnings Date | Nov 6, 2025 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
QQQM, GOOGL, ADBE, GILD: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco NASDAQ 100 ETF (Symbol: QQQM) where we have detected an approx...
GILD: JP Morgan Raises Price Target, Reaffirms Overweight Rating | GILD Stock News
GILD: JP Morgan Raises Price Target, Reaffirms Overweight Rating | GILD Stock News
Validea Detailed Fundamental Analysis - GILD
Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published strateg...
Notable Friday Option Activity: GSHD, GILD, EOSE
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Goosehead Insurance Inc (Symbol: GSHD), where a total of 2,556 contracts have traded so far...
Gilead, Moderna to see upside if RFK Jr. leaves HHS: RBC
Gilead Sciences, Inc. (GILD) Presents At Baird Global Healthcare Conference 2025 Transcript
VEEV Partners with Gilead Sciences to Enhance CRM with AI
VEEV Partners with Gilead Sciences to Enhance CRM with AI
Veeva Systems partners with Gilead for Vault CRM
Gilead a safe option for investors: Seigerman
Evan Seigerman, managing director at BioPharma Equity Research, joins BNN Bloomberg to share his Hot Picks in pharma.
Gilead (GILD) Partners with Global Fund for HIV Prevention Initiative
Gilead (GILD) Partners with Global Fund for HIV Prevention Initiative
Gilead Sciences (GILD) Teams Up with U.S. to Expand Lenacapavir Access
Gilead Sciences (GILD) Teams Up with U.S. to Expand Lenacapavir Access
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention ...
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries | GILD Stock News
Gilead joins U.S. efforts in expanding access to new HIV drug in low-income nations
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilea...
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief...
US plans to bring Gilead HIV drug to market in high-burden HIV countries
The U.S. State Department announced a plan on Thursday to bring Gilead Sciences Inc's drug lenacapavir to market "at cost" in high-burden HIV countries in an effort to reach 2 million people over thre...
Gilead Sciences, Inc. (GILD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Gilead Sciences highlights strong growth, successful Yeztugo HIV prevention launch, and
Gilead Sciences Launches Choose U Campaign Spotlighting the Inspiring Experiences of People Living with HIV
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of Choose U, a new campaign that spotlights the multifaceted experiences of people living with HIV globally. The timing of the campaign ...
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of Choose U™, a new campaign that spotlights the multifaceted experiences of people living with HI...
Gilead Sciences, Inc. (GILD) Presents At Cantor Global Healthcare Conference 2025 Transcript
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Gilead Sciences Inc (GILD) Breaks Ground on New Technical Development Center | GILD stock news
Gilead Sciences Inc (GILD) Breaks Ground on New Technical Development Center | GILD stock news
Gilead breaks ground on manufacturing development site at California HQ
Gilead Sciences breaks ground on an AI-enabled R&D hub, boosting US biotech innovation. Read more here.
Gilead starts building manufacturing hub under $32 billion planned US investments
Gilead Sciences said on Wednesday it has started work on a new pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, as part of its planned $32 billion inves...